분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2011-11-10 10:42:02 , Hit : 2434
 Gene Therapy Shows Promise as Hemophilia Treatment in Animal Studies

ScienceDaily (Nov. 3, 2011) — For the first time, researchers have combined gene therapy and stem cell transplantation to successfully reverse the severe, crippling bleeding disorder hemophilia A in large animals, opening the door to the development of new therapies for human patients.

Researchers at Wake Forest Baptist Medical Center's Institute for Regenerative Medicine, collaborating with other institutions, report in Experimental Hematology that a single injection of genetically-modified adult stem cells in two sheep converted the severe disorder to a milder form. The journal is a publication of the Society for Hematology and Stem Cells

"A new approach to treating severe hemophilia is desperately needed," said lead author Christopher D. Porada, Ph.D., associate professor of regenerative medicine at Wake Forest Baptist. "About 75 percent of the world doesn't have access to the current treatment -- therapy to replace missing clotting factors. This puts patients in most of the world at risk of severe and permanent disabilities."

Porada cautioned that challenges will need to be overcome before the treatment can be applied to humans, including that the sheep developed an immune response to the therapy that could decrease its effectiveness and duration.

There is currently no cure for the rare bleeding disorder hemophilia. People with this genetic disorder lack a protein, known as a clotting factor, needed for normal blood clotting. As a result, they may bleed for a longer time than others after an injury, as well as bleed internally, especially in joints such as the knees, ankles, and elbows. This bleeding can damage the organs and tissues and be life threatening. Even when life-threatening bleeds are prevented with replacement therapy, it doesn't prevent smaller bleeds within the joints that can cause pain and decreased mobility.

People with hemophilia A, the most common type, are missing clotting factor VIII. For the study, the researchers used a combined stem cell/gene therapy approach to increase levels of factor VIII produced by the animals.

The scientists first inserted a gene for factor VIII into engineered mesenchymal stem cells, a type of adult stem cell. The cells -- acting as a carrier for the gene -- were then injected into the abdominal cavity of the sheep. The scientists selected mesenchymal stem cells to carry the gene because they have the ability to migrate to sites of injury or inflammation.

In the treated animals, the cells migrated to the joints and stopped ongoing bleeding.In addition, all spontaneous bleeding events ceased, and the existing joint damage was completely reversed, restoring normal posture and gait to these crippled animals, and enabling them to resume a normal activity level.

However, a paradox of the treatment was that while the symptoms were eliminated, the sheep developed an immune response to factor VIII, suggesting that the treatment's effects would be reduced or shorter in duration. The scientists are currently working to learn why the immune response occurred and to develop strategies to prevent it.

"While preliminary, these findings could pave the way for a new therapy for hemophilia patients who experience debilitating bleeding in their joints," Porada said.

The research was supported by the National Institutes of Health.

Co-authors were Graça Almeida-Porada (senior author) and Chung-Jung Kuo , both with Wake Forest Baptist; Chad Sanada, Evan Colletti, Esmail D. Zanjani, Walter Mandeville and John Hasenau, all with the University of Nevada at Reno; Robert Moot, Aflac Cancer Center and Blood Disorders Service; Christopher Doering, Emory Children's Center Pediatrics; and H. Trent Spencer, Emory University School of Medicine.

Journal Reference:

Christopher D. Porada, Chad Sanada, Chung-Jung Kuo, Evan Colletti, Walter Mandeville, John Hasenau, Esmail D. Zanjani, Robert Moot, Christopher Doering, H. Trent Spencer, Graça Almeida-Porada. Phenotypic correction of hemophilia A in sheep by postnatal intraperitoneal transplantation of FVIII-expressing MSC. Experimental Hematology, 2011; DOI: 10.1016/j.exphem.2011.09.001







1067   Foamy 바이러스 벡터를 이용한 유전자 치료  이성욱 2008/02/12 5778
1066   Foot-and-mouth culls could be cut  이성욱 2011/05/11 3156
1065   Former Reginans changing the future of HIV  이성욱 2011/12/28 2256
1064   Fragile X syndrome: Trigger for most common form of intellectual disability and autism uncovered  이성욱 2014/03/05 1770
1063   Frances H. Arnold, George P. Smith, and Gregory P. Winter share 2018 Nobel Prize in Chemistry  이성욱 2018/10/04 358
1062   Friends connect on a genetic level  이성욱 2011/01/24 2262
1061   From Startups to Moguls] CRISPR 유전자가위 없이 편집한다? Homology Medicines  이성욱 2017/09/11 606
1060   Gene Editing Treats Blood Disease  이성욱 2011/07/16 3017
1059   Gene Study Based on RNA Interference May Lead to New Liver Cancer Therapies  이성욱 2017/08/14 810
1058   Gene Therapy Allows Beethoven Mouse to Hear  이성욱 2015/07/10 875
1057   Gene Therapy Appears to Help Patient With Anemia  이성욱 2010/09/17 2908
1056   Gene therapy drug approval granted to GSK  이성욱 2016/05/30 935
1055   Gene Therapy Ever More Common for Rare Disorders  이성욱 2018/05/30 333
1054   Gene Therapy for Controlling HIV Shows Early Promise  이성욱 2014/03/08 1600
1053   Gene Therapy for Immune Disorder Lasts Nine Years, Two New Studies Show  이성욱 2011/08/25 2479
1052   Gene Therapy May Thwart HIV  이성욱 2011/09/23 2056
1051   Gene therapy offers hope for Parkinson's disease  이성욱 2011/03/23 2352
1050   Gene Therapy Shows Promise Against Age-Related Macular Degeneration  이성욱 2011/05/04 2542
  Gene Therapy Shows Promise as Hemophilia Treatment in Animal Studies  이성욱 2011/11/10 2434
1048   Gene therapy trial on hold  이성욱 2007/08/07 4978

[이전 10개] [1].. 11 [12][13][14][15][16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN